Screener
Taysha Gene Therapies, Inc. TSHA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(42,410) | $(21,529) |
| Weighted-average shares of common stock outstanding used to compute net loss per common share, basic and diluted | 366,632,827 | 269,306,331 |
| Net loss per common share, basic and diluted | $(0.12) | $(0.08) |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s EPS (diluted)?
- Taysha Gene Therapies, Inc. (TSHA) reported EPS (diluted) of -$0.12 in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s EPS (diluted) changed year-over-year?
- Taysha Gene Therapies, Inc.'s EPS (diluted) decreased by 50.0% year-over-year, from -$0.08 to -$0.12.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s EPS (diluted) has grown at a -58.2% compound annual growth rate (CAGR), from -$4.64 to -$0.34.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Taysha Gene Therapies, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude